百利天恒：子公司izalontamab brengitecan获美国FDA突破性疗法认定

Core Viewpoint - The announcement highlights that SystImmune, a wholly-owned subsidiary of the company, has received Breakthrough Therapy Designation from the FDA for izalontamab brengitecan (iza-bren) for the treatment of locally advanced or metastatic non-small cell lung cancer with specific mutations after prior treatment failures [1] Group 1 - The Breakthrough Therapy Designation was granted based on multiple clinical trial data conducted in China and the United States [1]